Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 28

1.
2.

Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases.

Melo ME, Qian J, El-Amine M, Agarwal RK, Soukhareva N, Kang Y, Scott DW.

J Immunol. 2002 May 1;168(9):4788-95.

3.

Gene therapeutic approaches to induction and maintenance of tolerance.

Melo ME, El-Amine M, Tonnetti L, Fleischman L, Scott DW.

Int Rev Immunol. 2001 Oct;20(5):627-45. Review.

PMID:
11890616
4.

Neonatal exposure to antigen primes the immune system to develop responses in various lymphoid organs and promotes bystander regulation of diverse T cell specificities.

Pack CD, Cestra AE, Min B, Legge KL, Li L, Caprio-Young JC, Bell JJ, Gregg RK, Zaghouani H.

J Immunol. 2001 Oct 15;167(8):4187-95.

5.

Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit.

Costa GL, Sandora MR, Nakajima A, Nguyen EV, Taylor-Edwards C, Slavin AJ, Contag CH, Fathman CG, Benson JM.

J Immunol. 2001 Aug 15;167(4):2379-87.

6.

Gene therapy for tolerance and autoimmunity: soon to be fulfilled promises?

El-Amine M, Melo ME, Scott DW.

Clin Immunol. 2001 Apr;99(1):1-6. Review. No abstract available.

PMID:
11286536
7.

IgG Fc receptors.

Ravetch JV, Bolland S.

Annu Rev Immunol. 2001;19:275-90. Review.

PMID:
11244038
8.

IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis.

Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, Connors MA, Kurata H, Arai K, Haines GK, Kumar P, Koch AE.

J Immunol. 2001 Jan 15;166(2):1214-22.

9.

Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells.

El-Amine M, Melo M, Kang Y, Nguyen H, Qian J, Scott DW.

J Immunol. 2000 Nov 15;165(10):5631-6.

10.
11.

Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.

Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR.

J Clin Invest. 2000 Jul;106(2):245-52.

13.

CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice.

Takiguchi M, Murakami M, Nakagawa I, Saito I, Hashimoto A, Uede T.

Life Sci. 2000;66(11):991-1001.

PMID:
10724446
14.

Differential control of neonatal tolerance by antigen dose versus extended exposure and adjuvant.

Min B, Legge KL, Caprio JC, Li L, Gregg R, Zaghouani H.

Cell Immunol. 2000 Feb 25;200(1):45-55.

PMID:
10716882
16.

Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant.

Pulendran B, Smith JL, Jenkins M, Schoenborn M, Maraskovsky E, Maliszewski CR.

J Exp Med. 1998 Dec 7;188(11):2075-82.

19.

Is CTLA-4 a master switch for peripheral T cell tolerance?

Bluestone JA.

J Immunol. 1997 Mar 1;158(5):1989-93. Review.

PMID:
9036940
20.

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.

Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ.

J Exp Med. 1996 Nov 1;184(5):1953-62.

Supplemental Content

Support Center